Form 4: Akari Therapeutics Director Mohamed Wa'el Hashad Granted 5,000,000 Stock Options

Director Mohamed Wa'el Hashad of Akari Therapeutics Plc was granted 5,000,000 non-qualified stock options under the company's 2023 Equity Incentive Plan.

Summary

• Mohamed Wa'el Hashad, a director of Akari Therapeutics Plc, was granted 5,000,000 non-qualified stock options on June 28, 2024.
• The options have an exercise price of $0.001395 per ordinary share.
• The options were granted under the Issuer's 2023 Equity Incentive Plan.
• The stock options vest and become exercisable on the date of the Issuer's 2025 Annual General Meeting of Shareholders, subject to continued service with the Issuer.
• Hashad has also granted power of attorney to Rachelle Jacques and Wendy F. DiCicco to act on his behalf in matters related to securities filings.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The size of the grant and the vesting schedule are typical for incentivizing long-term performance and retention.
• Comparable companies such as BioCryst Pharmaceuticals and Sarepta Therapeutics also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates